

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1 – 9 (Canceled)

Claim 10 (Currently Amended): A liposome ~~wherein~~ comprising an antibody is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded antibody is 0.5 to 4.5 mg per 100 mg of total lipids that constitute the liposome, said antibody comprising a GAH antibody.

Claim 11 (Previously Presented): The liposome according to claim 10, wherein an amount of the bonded antibody is 1.2 to 2 mg per 100 mg of total lipids that constitute the liposome.

Claim 12 (Previously Presented): The liposome according to claim 10, which is obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

Claims 13-14 (Canceled)

Claim 15 (Currently Amended): The liposome according to claim 10, wherein a compound containing a polyalkylene glycol moiety is further bonded to a surface of the liposome separately from the antibody.

Claim 16 (Currently Amended): A liposome ~~wherein~~ comprising a bonded compound containing a polyalkylene glycol moiety bound to the liposome through thioether groups and ~~an~~ a separately bonded antibody bound to the liposome ~~are bonded~~ through thioether groups, ~~to a~~ said liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded compound is 15 to 30 mole% based on one mole of the maleimidated lipid, and an amount of the bonded antibody is 1.2 to 2 mg per 100 mg of total lipids that constitute the liposome, and said antibody comprising a GAH antibody.

Claim 17 (Original): The liposome according to claim 16, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

Claim 18 (Previously Presented): The liposome according to claim 16, wherein the compound is bonded to a surface of the liposome.

Claim 19 (Previously Presented): The liposome according to claim 16, wherein the polyalkylene glycol is polyethylene glycol.

Claim 20 (Original): The liposome according to claim 19, wherein the compound has two polyethylene glycol groups.

Claim 21 (Currently Amended): The liposome according to claim 20, wherein ~~the~~ each polyethylene glycol group has a molecular weight of 2,000 to 7,000 daltons.

Claim 22 (Original): The liposome according to claim 20, wherein ~~the~~ each polyethylene glycol group has a molecular weight of about 5,000 daltons.

Claim 23 (Previously Presented): The liposome according to claim 16, which is a liposome obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

Claim 24 (Canceled)

Claim 25 (Canceled)

Claim 26 (Previously Presented): A medicament composition for treatment of cancer comprising the liposome according to claim 11 and a medicament effective for treatment of cancer.

Claim 27 (Previously Presented): The medicament composition according to claim 26, wherein the cancer is stomach cancer or colon cancer.

Claim 28 (Previously Presented): A method for treatment of cancer which comprises administering to a patient the medicament composition according to claim 26.

Claim 29 (Previously Presented): A medicament composition for treatment of cancer comprising the liposome according to claim 10 and a medicament effective for treatment of cancer.

Claim 30 (Previously Presented): The medicament composition according to claim 29, wherein the cancer is stomach cancer or colon cancer.

Claim 31 (Previously Presented): A method for treatment of cancer which comprises administering to a patient the medicament composition according to claim 29.

Claim 32 (Previously Presented): A medicament composition for treatment of cancer comprising the liposome according to claim 16 and a medicament effective for treatment of cancer.

Claim 33 (Previously Presented): The medicament composition according to claim 32, wherein the cancer is stomach cancer or colon cancer.

Claim 34 (Previously Presented): A method for treatment of cancer which comprises administering to a patient the medicament composition according to claim 32.

Claim 35 (New): The medicament composition according to claim 26 wherein the medicament comprises doxorubicin.

Claim 36 (New): The medicament composition according to claim 29 wherein the medicament comprises doxorubicin.

Claim 37 (New): The medicament composition according to claim 32 wherein the medicament comprises doxorubicin.